MX383344B - Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. - Google Patents

Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.

Info

Publication number
MX383344B
MX383344B MX2017009122A MX2017009122A MX383344B MX 383344 B MX383344 B MX 383344B MX 2017009122 A MX2017009122 A MX 2017009122A MX 2017009122 A MX2017009122 A MX 2017009122A MX 383344 B MX383344 B MX 383344B
Authority
MX
Mexico
Prior art keywords
fluticasone propionate
dry powder
dose
salmeterol xinafoate
sub
Prior art date
Application number
MX2017009122A
Other languages
English (en)
Other versions
MX2017009122A (es
Inventor
Mukul Dalvi
Seah Kee Tee
Original Assignee
Teva Branded Pharmaceutical Products R&D Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55443303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX383344(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Branded Pharmaceutical Products R&D Inc filed Critical Teva Branded Pharmaceutical Products R&D Inc
Publication of MX2017009122A publication Critical patent/MX2017009122A/es
Publication of MX383344B publication Critical patent/MX383344B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
    • A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención proporciona un inhalador de polvo seco que comprende: un medicamento en polvo seco que comprende propionato de fluticasona, xinafoato de salmeterol y un portador lactosa; en el que la dosis suministrada de propionato de fluticasona por activación es inferior a 100 µg; y en el que la dosis proporciona un FEV1, ajustado a los datos de base de un paciente, de más de 150 mL dentro de los 30 minutos de haber recibido la dosis. Un método de tratamiento a un paciente incluye administrar a un paciente un medicamento en polvo seco que tiene propionato de fluticasona, xinafoato de salmeterol y un portador lactosa; en el que la dosis suministrada de propionato de fluticasona por activación es inferior a 100 pg; y en el que la dosis proporciona un FEV1, ajustado a los datos de base de un paciente, de más de 150 mL dentro de los 30 minutos de recibir la dosis.
MX2017009122A 2015-01-20 2016-01-20 Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. MX383344B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562105479P 2015-01-20 2015-01-20
PCT/US2016/014072 WO2016118589A1 (en) 2015-01-20 2016-01-20 Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat

Publications (2)

Publication Number Publication Date
MX2017009122A MX2017009122A (es) 2017-10-12
MX383344B true MX383344B (es) 2025-03-13

Family

ID=55443303

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017009122A MX383344B (es) 2015-01-20 2016-01-20 Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.
MX2021006751A MX2021006751A (es) 2015-01-20 2017-07-12 Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021006751A MX2021006751A (es) 2015-01-20 2017-07-12 Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.

Country Status (19)

Country Link
US (2) US20180015035A1 (es)
EP (1) EP3247331A1 (es)
JP (1) JP2018503687A (es)
KR (1) KR20170103975A (es)
CN (1) CN107530357A (es)
AR (1) AR104771A1 (es)
AU (2) AU2016209363B2 (es)
BR (1) BR112017015353A2 (es)
CA (1) CA2974125A1 (es)
CL (1) CL2017001859A1 (es)
CO (1) CO2017008395A2 (es)
EA (1) EA201791632A1 (es)
HK (1) HK1245125A1 (es)
IL (1) IL253499A0 (es)
MA (1) MA41378A (es)
MX (2) MX383344B (es)
PE (1) PE20171258A1 (es)
TW (1) TW201628607A (es)
WO (1) WO2016118589A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105636630B (zh) * 2013-10-07 2020-05-19 梯瓦优质制药产品研发股份有限公司 干粉吸入器
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
IL286777B2 (en) 2016-11-18 2025-03-01 Norton Waterford Ltd Drug delivery device with electronics
CN110201280B (zh) * 2018-02-28 2021-07-30 张江 用于吸入给药装置的吸嘴和吸入给药装置
CN110201278B (zh) * 2018-02-28 2021-07-30 张江 用于吸入给药的药盒和吸入给药组合结构
CN110201281B (zh) * 2018-02-28 2021-08-06 张江 吸入给药装置和吸入给药组合结构
CN110064110A (zh) * 2019-05-29 2019-07-30 上海理工大学 一种容积旋钮式干粉储存吸入装置
GB2585206B (en) * 2019-07-01 2021-08-11 Merxin Ltd Portable inhaler

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20020067A1 (es) * 2000-06-23 2002-02-05 Norton Healthcare Ltd Desaglomerador para inhalador de polvo seco accionado por la respiracion
TWI224513B (en) * 2000-06-23 2004-12-01 Norton Healthcare Ltd Dose counter for medicament inhaler
PE20020387A1 (es) * 2000-08-31 2002-06-24 Glaxo Group Ltd Uso de una combinacion de salmeterol y fluticasona
DK1920763T3 (da) * 2000-11-30 2014-07-07 Vectura Ltd Farrmaceutiske præparater til inhalation
GB0124523D0 (en) * 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
JP2006503865A (ja) 2002-09-30 2006-02-02 アキュスフィア， インコーポレイテッド 吸入のための徐放性の多孔性微粒子
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
EP3106149B1 (en) * 2009-05-29 2019-11-20 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta-2 adrenergic receptor agonists and associated methods and systems
US20110229437A1 (en) * 2009-09-17 2011-09-22 Mutual Pharmaceutical Company, Inc. Method of Treating Asthma with Antiviral Agents
GB0919465D0 (en) 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
KR101618933B1 (ko) * 2010-05-18 2016-05-09 아이박스 파마슈티컬즈 아일랜드 흡입기용 용량 계수기, 흡입기 및 그의 샤프트
EP2571486A4 (en) 2010-05-20 2013-12-04 Sun Pharma Advanced Res Co Ltd DRY POWDER INHALATION COMPOSITION
KR20130140358A (ko) * 2012-06-14 2013-12-24 한미약품 주식회사 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
CN105338965A (zh) * 2013-04-29 2016-02-17 赛诺菲股份有限公司 可吸入药用组合物和含有该药用组合物的吸入器装置
US9732025B2 (en) * 2013-05-03 2017-08-15 Dow Global Technologies Llc Process for equilibrium-limited reactions
CN105636630B (zh) * 2013-10-07 2020-05-19 梯瓦优质制药产品研发股份有限公司 干粉吸入器
CN107106514A (zh) * 2014-10-16 2017-08-29 梯瓦优质制药产品研发股份有限公司 干燥粉末配制剂
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol

Also Published As

Publication number Publication date
CN107530357A (zh) 2018-01-02
EA201791632A1 (ru) 2017-12-29
CL2017001859A1 (es) 2018-04-06
US9415008B2 (en) 2016-08-16
JP2018503687A (ja) 2018-02-08
AR104771A1 (es) 2017-08-16
KR20170103975A (ko) 2017-09-13
AU2016209363B2 (en) 2021-02-04
AU2016209363A1 (en) 2017-08-24
EP3247331A1 (en) 2017-11-29
HK1245125A1 (zh) 2018-08-24
US20160206559A1 (en) 2016-07-21
TW201628607A (zh) 2016-08-16
US20180015035A1 (en) 2018-01-18
CO2017008395A2 (es) 2018-01-05
PE20171258A1 (es) 2017-08-28
IL253499A0 (en) 2017-09-28
CA2974125A1 (en) 2016-07-28
AU2021202784A1 (en) 2021-05-27
MA41378A (fr) 2017-11-28
WO2016118589A1 (en) 2016-07-28
MX2021006751A (es) 2021-07-15
MX2017009122A (es) 2017-10-12
BR112017015353A2 (pt) 2018-01-16

Similar Documents

Publication Publication Date Title
MX374870B (es) Inhalador de polvo seco.
MX383344B (es) Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.
CO2019008487A2 (es) Compuesto de quinazolina
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
BR112014016672A8 (pt) compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
EA201370162A1 (ru) Новая фармацевтическая композиция со слабым побочным эффектом, включающая противотуберкулезные препараты
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
BR112018006206A2 (pt) composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
MX2018008196A (es) Tratamiento para cancer de mama usando una combinacion de una formulacion liposomal cationica de taxano, una formulacion no liposomal de taxano y un agente activo adicional.
BR112019001130A2 (pt) uso de lactama e composição farmacêutica
MY198201A (en) A Combination Medicament Comprising Phenylephrine And Paracetamol
MX2018005876A (es) Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.
AR102903A1 (es) Inhalador de polvo seco
MX387252B (es) EL USO DE DERIVADOS DE QUINOLINONAS QUE TIENE UNA ACTIVIDAD DE INHIBICIÓN DE LA FORMACIÓN DEL COMPLEJO DE C-Myc/Max/ADN EN EL TRATAMIENTO DE CANCER.
TH173838A (th) เครื่องพ่นละอองยาผงแห้ง
UY35901A (es) Nueva dosificación y formulación
BR112017018977A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de uma infecção por hepatite c ou uma condição resultante de uma infecção por hepatite c, em um hospedeiro em necessidade do mesmo e para fabricação de um medicamento direcionado para uso terapêutico para tratamento de uma infecção pelo vírus da hepatite c, uso de um composto, e, formulação farmacêutica?.
UA115063U (xx) Спосіб лікування собак із больовим синдромом при панкреатиті
RU2013106607A (ru) Способ лечения плевропульмональных осложнений у больных с острым панкреатитом